Holen Sie sich die Stockscreener-App
103.95
0.04%
0.045
Handel nachbörslich:
102.67
-1.285
-1.24%
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - MSN
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - MSN
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - MSN
BioNTech’s Promising PDAC Study: Market Implications and Progress - MSN
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment - TipRanks
Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study - TipRanks
BioNTech’s Promising Study on BNT113 and Pembrolizumab for Head and Neck Cancer - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
BioNTech’s Promising Phase 1/2a Trial: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Promising Phase II Study on MIUC: A Potential Game-Changer? - TipRanks
BioNTech’s BNT326 Study: A New Hope for Advanced Tumor Treatment? - TipRanks
Bristol-Myers Squibb and BioNTech SE Launch New Study on Pumitamig for Triple-Negative Breast Cancer - TipRanks
Pfizer and BioNTech’s New Study on Variant-Adapted COVID-19 Vaccine for Children: What Investors Need to Know - TipRanks
BioNTech SE’s Promising Phase II Study on Advanced Solid Tumors - TipRanks
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Pfizer and BioNTech’s New Vaccine Study: A Potential Game-Changer for COVID-19 Prevention - TipRanks
BioNTech’s Latest Clinical Trial: A Potential Game-Changer in Breast Cancer Treatment? - TipRanks
BioNTech’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
Pfizer and BioNTech’s Innovative Vaccine Study: A Potential Game-Changer? - TipRanks
Human Combinatorial Antibody Libraries Market to Surge USD 189.57 Million by 2034, Reports Towards Healthcare - GlobeNewswire Inc.
Sector Gamma AS Grows Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Probity Advisors Inc. Acquires New Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Clears Major Hurdle in CureVac Acquisition Process () - aktiencheck.de
Allianz Asset Management GmbH Acquires 2,815 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech Clears Final Hurdle for $1.25 Billion CureVac Acquisition () - aktiencheck.de
Aberdeen Group plc Grows Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Purchases 533 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Shell Asset Management Co. Buys 5,398 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Slow Capital Inc. Sells 3,415 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency? - The Globe and Mail
Why BioNTech Stock Jumped by Nearly 4% on Wednesday - The Globe and Mail
TB Alternative Assets Ltd. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
8.65%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):